Form 4: Zevra Therapeutics SVP, Finance & Corp Controller Reports Stock Option Grant and RSU Vesting

Timothy J. Sangiovanni, SVP, Finance & Corp Controller at Zevra Therapeutics, reports the vesting of restricted stock units and grant of stock options.

Summary

• On January 31, 2025, Timothy J. Sangiovanni, SVP, Finance & Corp Controller at Zevra Therapeutics, had 11,666 restricted stock units vest and settle into common stock.
• Also on January 31, 2025, Mr. Sangiovanni acquired 11,666 shares of common stock upon the vesting of these restricted stock units, increasing his direct holdings to 19,341 shares.
• On January 30, 2025, Mr. Sangiovanni was granted a stock option to purchase 38,000 shares of common stock at an exercise price of $8.02, which will vest in four equal annual installments beginning January 29, 2026.
• Additionally, on January 30, 2025, Mr. Sangiovanni was granted 19,000 restricted stock units, which will vest in three annual installments beginning January 30, 2026.
• Following these transactions, Mr. Sangiovanni directly owns 23,334 restricted stock units and a stock option for 38,000 shares.

Sentiment

Score: 7

Explanation: Routine insider transaction; positive as it aligns management interests with shareholders.

Positives

• The vesting of restricted stock units and grant of stock options align Mr. Sangiovanni's interests with those of the shareholders.
• The vesting schedule of the stock options and restricted stock units incentivizes continued service with Zevra Therapeutics.

Future Outlook

The remaining tranches of the restricted stock units will vest and settle in equal annual installments, subject to continued service. The stock options will vest in four equal annual installments beginning on the first anniversary of the grant date, also subject to continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of RSUs and granting of stock options are common compensation practices.

Comparison to Industry Standards

• Stock option grants and RSU vesting are standard compensation practices for executives in publicly traded companies, including those in the pharmaceutical and biotechnology sectors.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders may view the vesting of RSUs and granting of stock options as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the potential for similar equity-based compensation.

Key Dates